Omeros

Omeros appoints Mitro as vice president, sales and marketing

Tuesday, December 4, 2012 08:00 AM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company focused on products targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed Thomas A. Mitro as vice president of sales and marketing.

More... »

Omeros adds two new vice presidents to management team

Friday, October 19, 2012 02:21 PM

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

More... »

Omeros files IND application for lead compound in schizophrenia program

Monday, September 10, 2012 11:54 AM

Omeros, a Seattle-based clinical-stage biopharmaceutical company, has filed an Investigational New Drug Application (IND) with the FDA to initiate clinical trials evaluating OMS824, the company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.

More... »

Omeros begins enrollment in second phase III OMS302 trial

Wednesday, April 11, 2012 03:52 PM

Omeros, a Seattle-based biopharmaceutical company, has commenced enrollment in a second phase III clinical trial evaluating OMS302 in intraocular lens replacement (ILR) surgery.

More... »

Omeros' OMS302 reduces pain and pupil dilation in lens replacement post-op

Friday, March 16, 2012 04:51 PM

Omeros has reported positive data from its phase III clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery.

More... »

Omeros unlocks 20% of Class A orphans

Wednesday, November 30, 2011 01:02 PM

Omeros has reported that with its identification of compounds that interact
selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR19, GPR20, GPR31 and GPR141 - it has now unlocked over 20% of the 77 Class A orphans. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros is initially targeting Class A orphan GPCRs.

More... »

Omeros identifies four orphan GPCRs

Tuesday, September 13, 2011 10:49 AM

Omeros has identified compounds that interact selectively with each of four additional orphan G protein-coupled receptors (GPCRs) - GPR15, GPR39, GPR78 and GPR161. Omeros has now announced that it has unlocked 14 of the 80 Class A orphan GPCRs. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs. Omeros is initially targeting Class A orphan GPCRs.

More... »

Omeros unlocks orphan GPCRs linked to leukemia and sleep disorders

Wednesday, June 29, 2011 12:51 PM

Omeros said it has identified compounds that interact with orphan G protein-coupled receptors (GPCRs) P2Y8 and OPN4. P2Y8 (also known as P2RY8) is associated with acute lymphoblastic leukemia (ALL), an aggressive cancer of the white blood cells and the most common type of malignancy diagnosed in children.

More... »

Omeros advances OMS103HP and OMS302

Friday, May 20, 2011 10:49 AM

Omeros is advancing two of its product candidates from its PharmacoSurgery platform: OMS103HP for arthroscopic meniscectomy and OMS302 for intra-ocular lens replacement surgery; both candidates are going into phase III clinical development programs.  Additionally, the candidates have been added to standard irrigation solutions and delivered intra-operatively to the operative site throughout the surgical procedure to preemptively block the molecular-signaling and biochemical cascade caused by surgical trauma and to provide clinical benefits both during and after surgery.

More... »

Omeros publishes research on MASP-2 data

Wednesday, April 20, 2011 12:11 PM

Omeros has published research on mannan-binding lectin-associated serine protease-2 (MASP-2) in the April 18, 2011 early online edition of the Proceedings of the National Academy of Sciences (PNAS). Wilhelm Schwaeble, Ph.D., professor of immunology at the University of Leicester and the senior author of the paper, led an international team of researchers who demonstrated that blocking MASP-2 function significantly reduces tissue damage caused by ischemia-reperfusion injury.

More... »